{"slug":"retrospective","tag":"retrospective","variants":["retrospective"],"description":"No description yet","count":2,"kinds":{"paper":2},"related":[{"slug":"rgcc","tag":"rgcc","shared":2}],"records":[{"id":"paper-adar-rgcc-ctc-ovarian-ijgc-2026","kind":"paper","name":"Tailoring treatment for advanced and/or recurrent ovarian cancer using the response of circulating tumor cells to therapy: a retrospective analysis","route":"/key-papers/paper-adar-rgcc-ctc-ovarian-ijgc-2026/","tldr":"A single-centre review of recurrent ovarian cancer reported longer time before progression on a circulating tumour cell-guided treatment line than on each patient's previous line. The comparison was not randomised and cannot show that the assay caused the difference."},{"id":"paper-guadagni-rgcc-ctc-colorectal-bmc-cancer-2022","kind":"paper","name":"Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases","route":"/key-papers/paper-guadagni-rgcc-ctc-colorectal-bmc-cancer-2022/","tldr":"In 36 selected people with heavily treated colorectal cancer, a circulating tumour cell workflow predicted response with 47.2% overall accuracy and 5.3% specificity. There was no randomised comparison, and the assay was only one part of a complex treatment programme."}]}